Encompass Health Corporation (NYSE:EHC) Q2 2025 Earnings Call Transcript

Encompass Health Corporation (NYSE:EHC) Q2 2025 Earnings Call Transcript August 5, 2025

Operator: Good morning, everyone, and welcome to Encompass Health’s Second Quarter 2025 Earnings Conference Call. Today’s conference call is being recorded. [Operator Instructions] If you have any objections, you may disconnect at this time. I will now turn the call over to Mark Miller, Encompass Health’s Chief Investment Relations Officer.

Mark Miller: Thank you, operator, and good morning, everyone. Thank you for joining Encompass Health’s Second Quarter 2025 Earnings Call. Before we begin, if you do not already have a copy, the second quarter earnings release, supplemental information and related Form 8- K filed with the SEC are available on our website at encompasshealth.com. On Page 2 of the supplemental information, you will find the safe harbor statements, which are also set forth in greater detail on the last page of the earnings release. During the call, we will make forward-looking statements such as guidance and growth projections, which are subject to risks and uncertainties, many of which are beyond our control. Certain risks and uncertainties, like those relating to regulatory developments as well as volume, bad debt and cost trends that could actually — that could cause actual results to differ materially from our projections, estimates and expectations are discussed in the company’s SEC filings, including the earnings release and related Form 8-K, the Form 10-K for the year ended December 31, 2024, the Form 10-Q for the quarter ended March 31, 2025, and the Form 10-Q for the quarter ended June 30, 2025, when filed.

We encourage you to read them. You are cautioned not to place undue reliance on the estimates, projections, guidance and other forward-looking information presented, which are based on current estimates of future events and speak only as of today. We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain non-GAAP financial measures, for such measures, reconciliations to the most directly comparable GAAP measure is available at the end of the supplemental information at the end of the earnings release and as part of the Form 8-K filed yesterday with the SEC, all of which are available on our website. I would like to remind everyone that we will adhere to the 1 question and 1 follow-up question rule to allow everyone to submit a question.

If you have additional questions, please feel free to put yourself back in the queue. With that, I’ll turn the call over to President and Chief Executive Officer, Mark Tarr.

Mark J. Tarr: Mark, thank you, and good morning, everyone. Our discharge growth in the second quarter facilitated an increase of 12% in revenue and 17.2% in adjusted EBITDA. Total discharges for Q2 increased 7.2%, including 4.7% in same-store. Our discharge growth was again broad-based across geographies, payers and patient type. Our focus remains on successfully treating patients with complex medical conditions. Neurological conditions and stroke for which we have extensive clinical expertise, grew 12% and 6.7%, respectively, in the quarter. Our dedicated and highly competent clinical teams continue to deliver outstanding patient outcomes. Our Q2 discharge community rate was our discharge to acute rate was 8.5% and our discharge to SNF rate was 5.8%.

Our performance on each of these quality metrics is favorable compared to the industry average. In Q2, we opened a new 60-bed hospital in Fort Myers, Florida. We also added 26 beds to an existing hospital. In July, we opened a new 50-bed hospital in Daytona Beach, Florida and added 20 beds to an existing hospital. Over the balance of the year, we plan to open 5 additional hospitals, 4 for de novos with a total of 190 beds and a 50-bed freestanding satellite hospital and add another 30 to 50 beds to existing hospitals. Due in large part to our Q2 results, we are again increasing our 2025 guidance. The demand for inpatient rehabilitation services remains considerably underserved, and continues to grow as the U.S. population ages. The Medicare beneficiary population is the fastest-growing segment of the U.S. population.

It is estimated that by 2030, 1 in 5 Americans more than 70 million people will be aged 65 or older. The 65-or-older population has been growing consistently at a CAGR of approximately 3%. The average age of our Medicare beneficiary patient is 77 years old, and the aged 75-plus population is growing at approximately 4%, yet the supply of licensed IRF beds in the U.S. has increased only nominally. As a result, the demand for treatment of complex medical conditions such as stroke, necessitating earth care intensity is significantly underserved. We treat more patients with IRF appropriate conditions than any other provider. This allows us to develop and refine best-in-class clinical protocols which are then extrapolated across our hospitals via our continuous best practice initiatives.

The identification, development and implementation of these clinical protocols is enhanced by our state-of-the-art information systems, including our IRF specific electronic medical record. In addition to our strong performance on discharge community rate, we outperform industry averages on many quality, patient safety and patient satisfaction measures, including patients’ mobility at discharge their ability to care for themselves at discharge, medication management, pressure ulcers or pressure injuries that are new or worsened and patient Net Promoter Score. Referring hospitals know they can reliably spend complex patients to our hospitals for post-acute services. Our attractiveness as a partner to acute care hospitals is further evidenced by the fact that 67 of our 169 hospitals are operated as joint ventures.

Finally, on August 1, 2025, CMS released the 2026 IRF final rule. This included a net market basket update of 2.6% and which we estimate would result in approximately 2.7% increase in net revenue per discharge for our Medicare patients beginning October 1, 2025, and based on our current patient mix. With that, I’ll turn it over to Doug.

Douglas E. Coltharp: Thank you, Mark, and good morning, everyone. Revenue for the second quarter increased 12% to $1.46 billion and adjusted EBITDA increased 17.2% to $308.6 million. The revenue increase was comprised of 7.2% discharge growth a 4.2% increase in net revenue per discharge. Q2 net revenue per discharge benefited from a decrease of 90 basis points in bad debt expense to 2%. Recall that Q2 ’24 bad debt expense included reserves associated with significant increase in prepayment claims reviews under TPE. Q2 FWB per FTE increased 4%. Salaries and wages per FTE, excluding contract labor and sign-on and ship bonuses increased 3.4%. Contract labor and sign-on and shipped bonuses declined by $4.9 million or 15.1%. Contract labor FTEs represented 1.3% of total FTEs. Q2 benefit expense per FTE increased by 18%, and benefits expense growth continues to be driven by an increase in the frequency of high dollar medical claims.

We expect group medical expense growth to moderate in the second half of the year as we anniversary the increase we experienced in 2024. Net preopening and ramp-up costs were $4 million in Q2, taking the first half totaled to $6.1 million. We expect these costs for the full year to be in a range of $18 million to $22 million. Q2 adjusted free cash flow increased 30.5% to approximately $186 million, bringing year-to-date adjusted free cash flow to approximately $408 million a 31.7% increase from the first half of 2024. On the basis of our strong Q2 performance and the tax benefit of additional bonus depreciation resulting from recent legislation, we now expect 2025 adjusted free cash flow of $705 million to $795 million favorable. Our leverage and liquidity remain very favorable.

Net leverage at quarter end was 2x. We ended the quarter with approximately $100 million in unrestricted cash and in excess of $950 million available on our $1 billion revolving credit facility. During the second quarter, we repurchased approximately 232,000 shares of our common stock for $24.7 million. We recently announced an increase in our quarterly dividend next payable in October to $0.19 per share. As can be seen on Page 13 of our supplemental materials, we have again increased our anticipated growth CapEx estimate for 2025. You will recall that following Q1, we raised our estimated 2025 spend by $15 million to $20 million to pull forward a number of bed expansions in response to our increasing occupancy rates. We are now further increasing our 2025 estimated spend on bed expansion by $25 million, predominantly related to our recently announced CON approval for a freestanding hospital in Cleveland, Tennessee, which we intend to operate as a satellite of an existing hospital.

Production of this fully prefabricated hospital will commence shortly. We also added $5 million to our anticipated 2025 de novo spend as we have elected to accelerate the land purchase of a future period de novo. Moving on to guidance. We are raising our 2025 guidance as follows: net operating revenue of $5.88 billion to $5.98 billion, adjusted EBITDA of $1.22 billion to $1.25 billion and adjusted earnings per share of $5.12 to $5.34. The key considerations underlying our guidance can be found on Page 11 of the supplemental slides. And with that, we’ll now open the lines for questions.

Q&A Session

Operator: [Operator Instructions] We’ll take our first question from Andrew Mok of Barclays.

Andrew Mok: Occupancy rates have increased more than 200 basis points year-over-year through the first half of the year. I think some of that has benefited from a shift to single bed rooms. But if you just look purely at your single bedroom facilities, like where is mature occupancy? And what levels are you comfortable operating at?

Douglas E. Coltharp: Yes. So it varies pretty widely across the portfolio, really depending on the maturity of the hospital itself. First, to begin and give some of the specifics, the numbers that you’re looking at, Andrew. At the end of 2020, 41% of the beds in our portfolio were private. At the end of the second quarter, we were at 56%. To your point, occupancy in Q2 was 76.6%, and that’s up 210 basis points over the second quarter of last year. When we’re looking at an all private room facility, when the occupancy starts to stabilize north of 80%, we start putting it on a list — we put it on a list and start thinking about a future period bed expansion. Now the capacity in those facilities can run into the mid- to high 90s because you’re not facing issues of gender or germ compatibility.

It’s lower than that for the hospitals that are still semiprivate rooms. Recall, as we move into the back half of the year, based on the opening schedule that Mark highlighted during his comments, you’re going to see a little bit of a downward pressure on the occupancy because we’ve got that new capacity coming on board.

Andrew Mok: Great. And maybe just as a follow-up, there was some discussion of quality ratings in previous CMS rate proposals, but I don’t think any of that has moved forward yet. Just curious to get your thoughts on those initiatives, what would you be willing to — whether you support that and where you think you stand if those quality initiatives ultimately came to play.

Mark J. Tarr: Yes. Andrew, it’s Mark. So the quality initiatives, any change in those did not get included in the final rule. They did take out some of the ones around COVID that were COVID specific. When we work with our trade associations, we are fine with looking at and including various quality measurements and think that we would do extremely well on that. We just want to make sure as an industry that we all agree on what those would be and how they would be measured.

Operator: We’ll take our next question from Matthew Gillmor of KeyBanc.

Matthew Dale Gillmor: I just wanted to do a quick follow-up on Andrew’s question around quality. Can you just remind us how you share your quality results with different stakeholders? I guess I was thinking referral sources and JV partners. And are there any particular areas of quality that are sort of most relevant or important to those stakeholders?

Mark J. Tarr: Yes. So we work closely with Joint Commission. And a matter of fact, they do our Medicare validation surveys for all of our new start-up de novos. And relative to outcome metrics, the ones that we really focus on and share, although with our joint ventures, we can go as deep as they want to, but the ones we’re really focused on are discharge community, discharge to acute, discharge to SNF. And then we always include the patient satisfaction measurement with the Net Promoter Score. Those have all been prioritized by Medicare in the past. I think they are a good representation of the functionality of the patients at the time of discharge. And as you heard me in my prepared remarks, those are the ones that we do extremely well in.

We do well in others. There are 16 measurements as part of the CMS care compare. But we’re very proud of our outcomes and have been so for many years and continue to improve our outcomes. As a matter of fact, if you look at the discharge community as well as to acute, those were all the highest we’ve had in recent quarters. So we’re very proud of our quality and make it a priority.

Douglas E. Coltharp: In addition to the acute care hospitals, obviously, another important constituency are the physicians who refer patients to us and many oversee the care of those patients when they come into our facility. And they tend to be very data-driven. And so we share with them a lot of the patient improvement scores that Mark cited in his comments earlier today. So we’re looking at the gains that they have in functional capabilities and the ability to care for themselves and so forth. And again, that’s all — those are very numerically driven scores that physicians like to see and that they really study very hard.

Matthew Dale Gillmor: Great. I appreciate that. And then I wanted to ask a follow-up on payer mix. It seems like the Medicare fee-for-service mix was pretty stable this quarter, but maybe managed care ticked up a little bit. And I noticed you increased the — I think, your managed care pricing assumption. I was curious if there’s a story around that to tell or what’s driving that trend? Or perhaps it’s just within kind of normal variation of what you’d expect.

Douglas E. Coltharp: There actually is a bit of a story there, and that has to do specifically with the VA Community Care Network contract. And so we have been seeing — and that, again, is administered by 2 companies in the U.S. One is a division of Optum and the other is Tri-West. More of our hospitals fall under the administration of Optum. When I say it’s administered by those companies, it is on behalf of the VA. But unlike Medicare Advantage, the VA is still the party that is making authorization decisions regarding patients that are referred to that network. So over the last 3 years, we’ve seen growth in that line of business that’s been in the mid-teens. and it now comprises almost 18% of our overall managed care business. And importantly, it pays at the Medicare CMG. So that has been a driver of the growth in the managed care and also the improved pricing.

Operator: We’ll take our next question from Pito Chickering of Deutsche Bank.

Philip Chickering: Nice quarter. Looking at the EBITDA in the first half of the year for the back half of the year, can you sort of bridge to us sort of what the implied guidance is, how we should be thinking about start-up losses in the back half of the year, changes to employee per occupied bed in the back half of the year or any other changes as we bridge the first half of the year and the back half of the year?

Douglas E. Coltharp: Yes, absolutely. And so as we move into the back half of the year, we do expect to incur the lion’s share of the preopening and ramp- up costs. Again, if you’re at the midpoint of the $18 million to $22 million for the year and you subtract out the $6 million in the first half, you’re looking at about a $14 million number. We ran at a 2% bad debt number for the first half of the year. We hope that continues. But in our guidance assumptions, we’ve assumed that there is some resumption of TPE activity, which would cause that number to go higher. So pick your point for the second half of the year between 2% and 2.5%, you’d see an increase there. It’s a smaller number, but we had favorable insurance adjustments of about $4 million in the first half of the year.

We’re not necessarily anticipating that those would continue. Even though it was down on a year-over-year basis, the net EBITDA impact from provider taxes was about $7 million. There’s no guarantee that, that continues in the second half of the year. And then the item that you suggested is we ran at a 3.34 EPOB in the first half of the year. We expect that to be closer to 3.40, particularly given the new capacity coming on board in the second half of the year. Going the other way is the Q4 pricing update, at least a portion of which will be offset by our annual merit cycle. I think those are most of the pieces, Pito. I hope that was responsive to your question.

Philip Chickering: Yes. That’s perfect. Can you — in the script, you talked about it, but what was the premium labor in the first quarter versus second quarter sort of sequentially? Just looking at the contract employees, they’re basically flat sequentially. And I’m wondering if you saw a reduction overtime as you brought on more employees in the second quarter. And then any other comments you have on the ease of hiring today versus turnover on the full-time employees?

Douglas E. Coltharp: Yes. So sign-on and shift bonus from Q1 to Q2 in Q1, it was $12.2 million. It was $10.9 million in Q2. In terms of the shift bonus component, it was $10.7 million in Q1 and $8.4 million in — so nice improvement there. With regard to contract labor, we went from 16.4% in Q1, up just slightly to 16.7% in Q2. Contract labor FTEs, I think you actually hit this number, moved slightly from 375 to 379.

Mark J. Tarr: Peter, I’m going to ask Pat Tuer to weigh in on what he’s seeing in terms of labor. He and the operations team have been working real hard, specifically on the recruitment and the retention, as we’ve mentioned in past calls.

Patrick W. Tuer: Thanks, Mark. So we continue to see strong hiring. You may recall, a few years ago, we centralized our talent acquisition function. So we have 83 full-time employees that do nothing but focus on bringing people into our organization, and that encompasses both recruiters as well as the recruitment and marketing function. So we continue to see net hires up. We had 71 net hires in Q2, which is another strong quarter for us. And from a turnover perspective, we are hovering around pre-pandemic levels, just at 21%. That’s up slightly from Q1, but it is well below the turnover rates that we saw during the pandemic. And our local teams are focused on making sure that the employees in their markets are paid competitively.

We’ve also created a number of career ladders, and we’re focused on enrolling as many folks that qualify for those into those ladders. We have shown if we can get an employee, a nurse specifically on the clinical ladder, they’re turning over about 1/4 of the rate of our non-laddered nurses. So the other 2 things I’ll point out is from a retention standpoint, we’ve put some effort in the workflow analysis just to make sure that we’re reducing the burden on our clinical employees and making their workday as efficient as possible. And then another benefit of the centralized talent acquisition function is that with that recruitment function being centralized, our local HR folks have been able to focus more heavily on the engagement side, which has also helped retention.

Mark J. Tarr: A few of those turnover numbers were specific to nursing, which obviously has been a huge focus for us, too. But I mean we are also focused on therapy openings and making sure we retain our therapists as well. So I feel like we’re making some continued progress here in what continues to be a challenging market out there.

Operator: We’ll take our next question from Whit Mayo of Leerink Partners.

Benjamin Whitman Mayo: Maybe just a follow-up on the hiring efforts. I was just thinking that we never talked about the physiatrist market, only nurses and therapists. How does that market look like today? And maybe talk about how you find bringing doctors into new markets?

Mark J. Tarr: Whit, I’m going to ask Pat to deal on that. I will say before he gets some specifics, we have a team of physician recruiters here at Encompass, and that is somewhat centralized, but we’ve also had to use market and regional recruiters as well. I would say that overall, the pysiatry market is challenging, but has been fairly stable over the last 2 to 3 years. But I’ll let Pat give you some specifics.

Patrick W. Tuer: Thanks, Whit. So just a couple of specifics. We — so from market to market, this can vary, but I would say the supply has stabilized, as Mark has alluded. In a number of our markets, we partner with or have established residency programs with universities that have helped from a recruitment perspective. And then we also have a strong component of internal medicine physicians that also have worked to become rehab physicians in markets that may be challenging to get a PM&R physician. So I would say we’re — we have been able to fill all the needs that we currently have. And as Mark alluded, we have a pretty strong recruitment team that focuses solely on this.

Mark J. Tarr: It remains challenged. I will say over the last decade, we’ve seen a pleasant trend in what used to be 10 years ago, a lot of physiatrists primarily wanted to do outpatient and in some cases, pain management. And then we’ve seen a nice trend in the last couple of years where these physiatrists are very interested in inpatient setting and treating complex patients. So that’s been a nice little push as we’ve gone out to recruit doctors.

Benjamin Whitman Mayo: Okay. My follow-up is, I’m looking at my model here, and it’s got leverage now below 2x now. And are we not at a floor where you should look to maybe hold it steady and take that excess capital and prioritize larger buybacks? I appreciate the increase in the growth CapEx, but it seems like you can probably balance both.

Douglas E. Coltharp: Yes. The short answer is yes. So again, as we think about capital allocation, the top priority is going to continue to be towards capacity expansions. And as we noted in our comments, we have increased this year the allotment to both bed expansions and to de novos. We expect it to be at an elevated level for the next several years given the opportunity that exists to meet some of that rising demand. We do get a benefit both this year, it’s almost $50 million, and we’ll have an ongoing benefit related to bonus depreciation. So even as we increase our capital expenditures, we’re getting a favorable cash flow from the tax benefit also. And so the likely place to go is going to be with more share repurchase activity.

Operator: We’ll take our next question from Joanna Gajuk of Bank of America.

Joanna Sylvia Gajuk: So I guess maybe first, I guess, the follow-up on the last, I guess, discussion around the capital deployment priorities such is there likely more share repo. Any considerations around acquisitions? I think I’ve asked you this before. It sounds like you believe when it comes to your core business, the inpatient we have, you believe de novos and bed additions still we prefer those because of the returns over deals. But any consideration around looking outside of the inpatient rehab? I just want to ask just in case.

Douglas E. Coltharp: Right now, we have not identified any particular service lines or capabilities that are important to our key constituencies that we don’t currently provide. And so there are no adjacencies that are on our radar screen to move into. We would consider those only to the extent some of those key constituencies, whether it was referral sources or payers came to us and said, you could be meaningfully more valuable to us as a partner if in addition to IRF services, you could do this additional thing. And that has not arisen in any of our discussions yet. With regard to acquisitions within the IRF space, we continue to use the model as part of our business development effort where we will acquire a unit in an existing hospital and have it folded into a new de novo as a market entrant strategy.

That will continue to be an arrow that we have in our quiver. As we’ve mentioned before, there are some portfolios of freestanding IRFs that are out there predominantly sponsored by private equity. Some of those have experienced attractive growth and have some favorable operating characteristics. As those become available, we would probably evaluate those, but it’s a pretty high bar to surpass the returns that we’re getting from our de novo activity. So the real focus of our cash flow and our capital allocation in terms of capacity expansion is going to be — is going to remain on our own de novo activity and then bed expansions at existing hospitals.

Joanna Sylvia Gajuk: And my question about the same-store volumes were up very nicely in the quarter. Can you talk about, I guess, the metrics by specialty? Sometimes you give us these metrics. So just curious about whether there’s any outlier or every kind of categories going similarly?

Douglas E. Coltharp: Yes. So we can provide you with some of that. So if we look — and Mark hit on some of these numbers in his comments in the quarter, neurological was very strong, up 12.5%. We saw another good quarter of stroke growth. That was up 6.7%. Brain injury is a smaller, but still a significant category. That was up over 12%. So good growth in a lot of those areas where we focused in terms of being able to treat more medically complex, higher acuity patients. That’s been a portion of our differentiation strategy for more than a decade now.

Operator: Our next question is from Ann Hynes of Mizuho Securities.

Ann Kathleen Hynes: I know there is a few CON states that might relax the CONs, maybe North Carolina, South Carolina and Tennessee. Can you just give us the update on the status of those and maybe how you view de novo activity in those states once the CONs are lifted?

Mark J. Tarr: Yes, we have a presence, as you know, in South Carolina, up to and all around the Charlotte marketplace that their CON will subside January 1, 2027. There is a lot of discussions among many within the decision-makers in the state of North Carolina. We have one hospital now in the state of North Carolina in Winston-Salem and believe that, that state with its growth and its demographics and its shortage of rehab beds would be a state that would look not dissimilar to what Florida had looked for us in terms of our ability to be a first mover in the state and have a significant number of attractive markets in which to pursue.

Ann Kathleen Hynes: Perfect. And then on — a big theme is this quarter with the payers is just increased coding and maybe more of the use of AI with documentation. How is Encompass using AI to code and document better?

Douglas E. Coltharp: Yes. So we’ve mentioned previously, we do have a partnership with Palantir and what we’re really looking to do is utilize AI, and Pat mentioned this in some of his remarks earlier, to reduce the administrative burden on our staff and also just to improve the consistency with which we’re presenting information. It also allows us, for instance, when we get a medical record on a patient who is transferring to us from an acute care hospital it is voluminous. And it’s very taxing on our staff to have to come through that record and make sure that we’re pulling forward the most pertinent information into our own documentation and AI can really facilitate that process. Now nothing that we’re doing with AI is overriding individual clinical judgment.

We make sure that there is a stringent manual review of these processes as well. But it is a tool that ultimately we think can reduce administrative burden, improve accuracy and in so doing, also increase the job satisfaction of our staff.

Mark J. Tarr: And one specific application of that has been used by our nurse liaison to go out and do patient evaluations, which can take a lot of time and many of these patients don’t turn into admissions. So I mean, anything we can do to help these nurse liaisons become more efficient, and we’ve done that working with Palantir as they use their iPad to do the assessment and all the documentation around that. And we’ve been able to reduce the time for documentation of that assessment by 20 minutes, which you start multiplying that out by all the liaisons that we have and the patients that are being evaluated, and you can see a significant gain in efficiency. And it’s also a job satisfaction plus for those liaisons. But that’s just one specific application of how we’re applying AI and the use of working specifically with Palantir and Oracle in some cases.

Douglas E. Coltharp: And ultimately, it inures to the benefit of both the acute care hospital as the referral source and the patient. It allows us to be more responsive and respond faster, which has the potential to free up that bed in the acute care hospital. It also means that if we can make a faster decision and the patient comes into our facility, they’re going to start their therapy regime earlier, which has substantial clinical benefits.

Patrick W. Tuer: Ann, I was just going to add, this is Pat. We also use predictive analytics and modeling to help us with our fall risk model. So since 2020, when we implemented this model, our fall rate has improved by 30%. And that model looks at 50 different clinical elements, consolidates those into a risk score and informs our clinicians of the patients that enhanced fall risk. And then the other is on acute care transfers. Back in 2015, we developed a REACT model, which continues to be refined, and that has led to a rate improvement of 24% since 2020. So 2 other examples of where we’re using predictive analytics within our systems to help improve quality in the clinical process.

Operator: We’ll take our next question from A.J. Rice of UBS.

Albert J. William Rice: Just on the managed care contracting, any it out from a couple of other questions. Anything with the pressure that they’re experiencing changes in the dynamics, terms, discussion and rate updates you’re seeing?

Douglas E. Coltharp: A.J., you were a little bit garbled there. I think the question was specifically around managed care contracting. As we go through some of the renewals, are we seeing anything that is significantly different from recent historical? I mentioned earlier because it’s contained within the managed care bucket for us on payer mix, the impact of the VA work in the community care network that has been very favorable, and that’s led to the higher-than-anticipated price increase there. Also good growth because it’s been increasing the last 2- plus years at a growth rate in the mid-teens. Other than that, I’d say it’s been fairly standard in terms of annual price increases kind of in that 2.5% to 3% range and volume growth is not all that significant.

Albert J. William Rice: Okay. And then another one, you’re pacing on de novo new deals, partnerships, et cetera, has been very steady, if not improving — increasing a little bit. But I always want to be aware of the pipeline and what you’re seeing out there. Have the discussion with acute care partners and potentials on JVs and things like that? Is there any change in that or in the depth of the potential backlog that you see? Anything to call out there?

Douglas E. Coltharp: No. We included in the supplemental slides, the development activity that has been announced, and there are 18 projects, including those that have already opened up this year. Consistent with what we’ve said before, we maintain an active dialogue or an active pipeline of right at about 50 projects, and it’s stayed pretty steady at about that level. So I feel good about the visibility to continue at this level of growth for the next several years.

Mark J. Tarr: A.J., I think one thing that’s notable on this development list is the fact that we’re growing not only in states where we already have a presence like such as Pennsylvania or Georgia, but we also have some new states that we’re entering, and we’ll open up our first hospital in Danbury, Connecticut here in Q3. And then we’ll also be in the outer years, we’ll be looking at adding hospital in Utah and another out in Nevada. So we’re looking at where we have market density as well as some opportunities to open up in new states.

Operator: We’ll take our next question from Jared Haase of William Blair.

Jared Phillip Haase: Maybe I’ll ask one around the benefits expense. And I think you said that was up 18% in the period. A couple of quick ones. One, just can you remind us the split in total SWB spend between wages and benefit costs? And then I assume much of that growth is driven by kind of specialty pharmaceuticals, but just wanted to confirm that. And then I guess with that being the case, assuming things like specialty pharmaceuticals are a big driver, it doesn’t seem like that’s going away anytime soon. So I’m wondering if there’s anything incremental to sort of your strategy to manage benefits expense going forward?

Douglas E. Coltharp: Yes. So a lot to unpack there. So in response to the first question, total benefits runs at about 10.5% of the total SWB line, right between 10.5% and 11%, even with the recent increases that we’ve seen. The double-digit increases that we’ve been seeing for the last year have been driven predominantly by an increased frequency of high dollar claims, which we typically classify as an individual claim of over $100,000. Some of that is due to overall inflation in the health care system. So those patients, even if they’re experiencing a malady similar to what they had previously, whereas the cost of treatment may have been less than $100,000, it’s over $100,000. It’s not really been driven by the specialty pharma with one exception that I’ll go through in a minute.

And so I think when a lot of folks think of specialty pharma, you’re thinking of things like the GLP-1s and then also some of the other notable drugs that we see out there like KEYTRUDA and so forth. And what we’ve seen there is that the rate of increase in terms of our spend on those drugs has been relatively modest, kind of in the mid-single-digit increase, and that’s because rebates have kept pace with the increased spend on those drugs. Where we are seeing the impact of specialty drugs is with some of the cancer treatments. And that gets picked up in the medical claims versus the pharma claims because those are administered on an inpatient basis.

Jared Phillip Haase: Got it. That’s really helpful color. I appreciate all that. And then maybe just as a quick follow-up, I’ll ask on free cash flow. A nice quarter. I think it was up about 31%. If I look at the revised guidance, I think it implies about 9% or so for the full year, 9% growth. I think you kind of clarified some of the bridging items in the second half and sort of the timing of the capital investment. But maybe the question, if I think longer term, any guardrails or parameters you would frame in terms of how we should think about free cash flow growth going forward, either in terms of a total annual growth rate or conversion relative to EBITDA?

Douglas E. Coltharp: Yes. I think it’s going to be relatively similar. So I think that CapEx is going to be roughly similar over the next several years. Obviously, we would anticipate further growth in EBITDA. And as we mentioned earlier, we’ve gotten a benefit this year and would expect to see a benefit over the next several years as well. from the change in the tax legislation regarding bonus depreciation. And so that should enhance the flow-through.

Operator: We’ll take our next question from Brian Tanquilut of Jefferies.

Brian Gil Tanquilut: Congrats on the quarter. Maybe just a question, Doug. As I think about tariffs and I know you’re expanding your CapEx budget for the year. Are you seeing any changes there that we need to be thinking about as we think through 2026 budgeting for CapEx and construction costs?

Douglas E. Coltharp: Not yet. Obviously, there’s still a whole lot that is in flux. We’ve talked previously about how we source our materials. We don’t have a lot of exposure, for instance, to concrete, which is predominantly sourced out of Mexico, given the building composition. From a steel perspective, a lot of the steel that we use is recycled steel that we’re able to procure in the U.S. So thus far, we haven’t seen a pronounced impact from tariffs on construction cost inflation, but it’s obviously something that remains in flux for everybody who’s out there, and we continue to keep an eye on.

Brian Gil Tanquilut: I appreciate that. And then maybe, Mark, I appreciate all the comments on the quality and the discussions you’re having with the JV partners. Maybe curious if you can share with us any feedback or any discussions since July that you or your staff and your team have had with the referral partners.

Mark J. Tarr: Yes. So Brian, we were very transparent and reached out to our partners. We are aware that — this article may come out. We didn’t know when it’s going to come out. We didn’t know what it was going to say, but we reached out to all of our partners and said this may be out there. We have always been transparent with our partners relative to our quality outcomes or anything that might be out in terms of changes in regulations or otherwise. But I think that our partners certainly are referring physicians, are referring hospitals and the patients themselves recognize our quality. And as it leads to the outcomes that we can get relative to return back to the community or the Net Promoter Score or their likelihood or low likelihood of being readmitted back to the acute care hospitals, and that’s what they appreciate.

We think it’s — the article that took 0.001% of our total discharges for that time period reviewed in the article and tried to use that to cast what we would consider to be a mischaracterization across our quality was disappointing.

Operator: We’ll take our next question from Raj Kumar of Stephens.

Raj Kumar: Just kind of looking at this is 12 straight quarters of same-store discharge growth above 4%. Maybe kind of just balancing insights from upstream acute care hospital providers and how they’re seeing moderating volume growth to more normalized levels. And then also kind of a tougher comp backdrop for Encompass. How do you see same-store growth in the back half? And then there’s a lot of new facilities coming online in the back half as well. So maybe kind of providing a framing of growth relative to that 6% to 8% target in the back half between same-store and new store?

Douglas E. Coltharp: I think you’ve hit on the right factors, which is you’re going to have more capacity coming on board in the second half, which will help in terms of new store growth. But some of that capacity is coming on very late in the year. So it’s not going to impact this year as much as it will benefit next year in terms of new store growth. From a same-store perspective, you’re absolutely right. It’s great. We’ve had 12 consecutive quarters north of 4%. That has raised the bar in terms of the comp that we’re up against. As it relates to what you may be seeing upstream at the acute care hospitals, just a reminder that although it feels like because we get in excess of 90% of our referrals from acute care hospitals that there ought to be a high correlation between our volumes and acute care hospitals, but it does not exist.

And it does not exist because only less than 5% of the patients being discharged from acute care hospitals in the U.S. wind up going to the IRF setting. And that portion of their volume because it relates to nondiscretionary illnesses that ultimately qualify for treatment in an IRF are not very volatile. So the volatility that the acute care hospitals see that we do not is predominantly around discretionary treatments.

Raj Kumar: Got it. And then maybe just separately on a smaller portion of the business, outpatient visits was up nicely sequentially, although still down year-over-year and then pricing has been going up drastically in that business as well. So maybe what was that driver of growth? Was it kind of like a onetime surprise like we saw on like fee-for-service and inpatient side in the first quarter? Or is there something being strategically done to maybe stabilize that business since pricing has been kind of accommodated?

Douglas E. Coltharp: So is your question more — yes, is your question more about outpatient revenue or outpatient volume because the outpatient revenue increase is largely attributable to the increase in Medicaid supplemental payments. That category is outpatient and other, if you’re looking at Page 5 of our supplemental slides.

Raj Kumar: Yes, I was more referring to just volumes was kind of up 8% quarter-over-quarter, which is seems much more higher than how it has been historically between 1Q and 2Q.

Patrick W. Tuer: Thanks, Raj. This is Pat. So outpatient, we only have a small number of locations, and we have intentionally lowered that footprint over time, including the closure of 3 outpatient facilities within the last year. So I would just say that the operations that we still have running have a good book of business. They’re well known in their communities, and they often are specialized from an outpatient therapy perspective that draws volume in. So I wouldn’t say that it is a nationwide intentional strategy, but a very market-specific strategy with the teams that have outpatient in their communities.

Operator: Thank you. And it does appear that we have no further questions at this time. I’d be happy to return the call to Mark Miller for any closing comments.

Mark Miller: Thank you, operator. If anyone has additional questions, please call me at (205) 970-5860. Thank you again for joining today’s call.

Operator: Thank you. This does conclude today’s conference. You may now disconnect your lines, and everyone, have a great day.